NCT00275028View on ClinicalTrials.gov

AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

January 31, 2011

Conditions
Fallopian Tube CancerPrimary Peritoneal Serous AdenocarcinomaRecurrent Ovarian Epithelial CancerStage I Ovarian Epithelial CancerStage II Ovarian Epithelial Cancer
Interventions
DRUG

cediranib maleate

Given orally

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00275028 - AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter